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BACKGROUND: High-resolution mass spectrometry
(HRMS) has the potential to supplement other drug
screening platforms used in toxicology laboratories.
HRMS offers high analytical specificity, which can be
further enhanced by incorporating a fragment ion for
each analyte. The ability to obtain precursor ions and
fragment ions using elevated collision energies (MSE)
can help improve the specificity of HRMS methods.
METHODS: We developed a broad-spectrum screening
method on an ultraperformance liquid chromatogra-
phy TOF mass spectrometer (UPLC-TOF-MS) using
the MSE mode. A diverse set of patient samples were
subjected to a simple dilute, hydrolyze, and shoot pro-
tocol and analyzed in a blind manner. Data were pro-
cessed with 3 sets of criteria with increasing stringency,
and the results were compared with the reference lab-
oratory results.
RESULTS: A combination of retention timematch (0.2
min), a protonated analyte, and fragment ion mass ac-
curacy of5 ppm produced zero false-positive results.
Using these criteria, we confirmed 92% (253/275) of
true positives. The positive confirmation rate increased
to 98% (270/275) when the requirement for a fragment
ion was dropped, but also produced 53 false positives.
A total of 136 additional positive drug findings not
identified by the reference methods were identified
with the UPLC-TOF-MS.
CONCLUSIONS: MSE provides a unique way to incorpo-
rate fragment ion informationwithout the need of pre-
cursor ion selection. A primary limitation of requiring
a fragment ion for positive identification was that cer-
tain drug classes required high-energy collisions, which
formed many fragment ions of low abundance that
were not readily detected.
© 2014 American Association for Clinical Chemistry
In the early part of the last decade, the toxicology com-
munity witnessed the arrival of high-resolution mass
spectrometry (HRMS)3 (1–3). The number of reports
onHRMS in toxicology laboratories is steadily increas-
ing (4 ). HRMS offers some unique advantages over
low-resolution MS and/or tandem MS (MS/MS).
HRMS can provide greater specificity due to its in-
creased resolving power. An HRMS instrument also
provides the opportunity for retrospective analysis,
since data are typically acquired over a widemass range
in a full scanmode.Unlike targeted acquisitions such as
multiple reaction monitoring (MRM), one can obtain
and analyze HRMS data to detect “unknown un-
knowns” present in a sample without having reference
standards.
During the introductory period of HRMS in toxi-
cology laboratories, use of accurate mass with a rela-
tively wide (20 ppm) mass error window was re-
ported for identifying unknowns (2 ). Under such
conditions, false-positive results could occur because
endogenous analytes and environmental contaminants
in a complex biological matrix might fall within the
mass error window used for analysis. Other reports
demonstrated that the number of false positives could
be reduced by narrowing the mass error window (5 ),
incorporating themetabolic pattern (6 ), and using iso-
tope patterns (7 ). Comparison of ultra-HRMS (reso-
lution 100 000 at m/z 200) with HRMS (resolution
10 000 at m/z 200) has also been reported for toxico-
logical screening purposes (8 ). That report stated that
under the given conditions, ultra-HRMS did not lower
the number of false-positive results compared with
HRMS. The number of false-positive results also de-
pends on how the collected data are analyzed. In gen-
eral, numbers of false-positive results go up in propor-
tion to the number of entries in a database being
searched (9, 10).
Fragment ion information can be used to increase
the analytical specificity and hence lower the false-
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positive rate. Collision-induced dissociation (CID) is
commonly used to obtain fragment ion information.
CID spectra can be obtained by performing dissocia-
tion in the ion source (source-CID) or in a collision
cell. Use of source-CID has been reported in confirm-
ing the positive findings in hair sample analysis (11).
The CID spectra obtained by this approach are less re-
producible because (a) it does not involve precursor
ion selection and (b) there are many factors that can
influence fragmentation of ions in the source such as
source gas pressure, source voltages, coeluting com-
pounds, neutral particles, temperature, and solvents.
There are 2ways to carry outCID in a collision cell.
In the first approach, before colliding ions in a collision
cell, precursors of interest can be selected in a quadru-
pole that provides information on ion lineage (e.g., a
certain fragment ion originated from a selected precur-
sor ion). Pavlic et al. used a hybrid tandem quadrupole
TOF MS analyzer to develop a library of product ion
spectra at various collision energies in the collision cell
(12). Information-dependent fragmentation of quali-
fying analytes has also been used (1, 13). It involves a
preselection criterion for identifying ions for fragmen-
tation. During data acquisition, any ion that meets or
exceeds the set intensity threshold is selected for frag-
mentation, producing specific diagnostic ions for iden-
tification purposes.
The second approach to performing CID in a col-
lision cell involves sending all ions generated in the ion
source into the collision cell. These ions can be sub-
jected to low-energy collisions to obtain protonated ana-
lytes or elevated energy collisions to form fragment ions
(MSE ). A primary advantage of CID in a collision cell
compared with source CID is that most of the neutral
molecules do not reach the collision cell. This approach
provides a true broad-spectrum screen, since no ions
are deliberately excluded. MSE combines fragment ion
information into algorithms for identifying unknowns
(14). MSE uses a collision cell before m/z separation
and acquires data in a dual-scanning mode. The first
scan applies a fixed low voltage to the collision cell.
Because ions do not undergo significant fragmentation
at this low collision energy, this scan generally provides
intact protonated ion information for all analytes. A
second high-energy scan alternates with the low-
energy scan to acquire data with a collision energy
ramp. All ions entering the collision cell experience the
collision energy ramp and undergo fragmentation to
provide fragment ion information.
In this investigation, we set out to answer the fol-
lowing practical questions before implementing this
methodology in a toxicology lab: (a)What are the best
set of data processing criteria for producing results
comparable to reference methods? (b) Can MSE
match the performance of traditional MRM-based
LC-MS/MS methods with a variety of matrices? (c)
Can MSE function with a dilute, hydrolyze, and
shoot (DHS) method? and (d) Does fragment ion
information improve the analytical specificity of this
methodology?
Materials andMethods
Details about materials, TOF-MS lock spray settings,
unit resolution LC-MS/MS conditions, and analyte se-
lection are available in the Supplemental Data, which
accompanies the online version of this article at
http://www.clinchem.org/content/vol60/issue8.
LC CONDITIONS
Chromatographic separation was achieved by ultraper-
formance liquid chromatography (UPLC) (Waters
Corp.). We used a UPLC BEH C18 guard column (1.7
m, 5 mm) and an analytical column (1.7 m, 2.1 
150mm)with flow rate of 0.4mL/min at 50 °C.Mobile
phase A and B were 5 mmol/L ammonium formate
(pH 3) and 0.1% formic acid in acetonitrile, respec-
tively. Five percent B was maintained for initial 0.5
min, increased in a linear fashion to 50% B at 6 min,
and then to 95%B at 7min, where it was held for 2min.
Reconditioning of the columns was achieved by drop-
ping the gradient to 5% B at 9.05 min and maintaining
it for 2.0 min.
TOF MS CONDITIONS
Weused aTOF-MS (XevoG2TOF;WatersCorp.)with
a resolution of approximately 20 000 (full width at half
maximum at m/z 400); cone voltage, 20 V; capillary
voltage, 0.8 kV; source block temperature, 130 °C; and
desolvation gas flow 1000 L/h at 450 °C. Data were ac-
quired in profile mode with MassLynx software, version
4.1, SCN862 (Waters Corp.) without real-timemass cor-
rection. The MS method consisted of 3 functions. Func-
tion 1 acquired data over the 50- to 650-m/z range with a
6-eV collision energy (low energy). Function 2 acquired
sample data over a 50- to 650-m/z range with a collision
energy ramp of 10–50 eV (high energy). Function 3 ac-
quired lockmassdataover a50- to650-m/z range.UNIFI,
version 1.6.1 (Waters Corp.), was used for data process-
ing, which involvedmass correction by use of leucine en-
kephalin data acquired simultaneously with each sample.
The database was built for 61 analytes and included the
retention time, molecular formula, and fragment ion in-
formation for each analyte.
A separate MRM-based LC-MS/MS (UPLC-Xevo
TQ-S) was developed specifically for confirming posi-
tives tentatively identified by the UPLC-TOF-MS
method that were not identified by the reference labo-
ratories. The tandem instrument used was more ana-
lytically sensitive than the UPLC-TOF-MS under in-
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vestigation. We used 2 MRM transitions for each
analyte, and the sample preparation and LC conditions
used for these analyses were exactly the same as those
used in UPLC-TOF-MS analyses. Other details of the
MRM-based LC-MS/MS method are presented in the
online Supplemental Data.
SAMPLE SOURCES
Our goal was to obtain samples from different sources
that would represent the variety ofmatrices commonly
encountered by toxicology laboratories.We obtained 4
sets of samples from 3 different sources. These 4 sets
were clinical toxicology samples that screened positive
for opiates (set 1) and benzodiazepines (set 2), post-
mortem samples (set 3), and samples from pain man-
agement patients (set 4). These samples had previously
been analyzed by LC-MS/MSorGC-MSusingMRMor
selected ion monitoring methods, respectively. The re-
sults of the initial analyses were kept blind until com-
pletion of UPLC-TOF-MS analysis.
SAMPLE PREPARATION
We added 400L deionized (DI) water to a vial followed
by 100 L internal standard solution (1 ng/L mix of
amphetamine D5, codeine-D3, diazepam-D5, oxazepam-
D5, and venlafaxin-D6) in methanol and 200 L urine
sample. We added 300 L -glucuronidase solution
(5000 U/mL) prepared in a 1.0-mol/L sodium acetate
buffer (pH 5) and mixed the solution by inversion. The
mixture was incubated at 50 °C for 90 min followed by
cooling and centrifugation at 2010g for 10min. Superna-
tant (20L) was injected for analysis.
MATRIX EFFECT
We selected samples from 13 different patients because
they had abnormal color (red, brown, black, etc.)
and/or because of turbidity (clear, slightly turbid, ex-
tremely turbid). These samples were presumed to be
indicative of a greater matrix complexity than would
commonly be encountered. We also obtained 5 sam-
ples from healthy volunteers to represent samples that
are more typically encountered in clinical practice. To
study matrix effects specifically, these 18 samples were
analyzed by DHS for the presence of all 61 analytes to
evaluate if they contained any of the compounds of
interest. These samples (and DI water) were then
spiked with a mixture of all 61 analytes at 100- and
1000-ng/mL concentrations. In addition to these 18
samples, we analyzed 61 samples during the correlation
study, which also represented a variety of different
urine matrices. Matrix effect was calculated by the fol-
lowing formula; 100 [(response in samples/response
from spiked DI water)  100]. Hence, a higher value
indicated greater ion suppression.
SPECIFICITY
Six groups of compounds were spiked at 500 ng/mL in
the starting gradient matrix (95:5 mobile phase A:B)
and analyzed onUPLC-TOF-MS. This experiment was
performed to establish target retention times, identify




Compared to other techniques, the DHS methodol-
ogy is fast, allows for a 1-vial procedure, and has
low cost of consumables per sample (15 ). Broad-
spectrum screening methods require that none of
the analytes are lost during the sample preparation.
With techniques such as liquid-liquid extraction and
solid-phase extraction, there is a risk of losing an
analyte during the isolation steps. Because DHS has
no purification steps, it avoids potential loss of ana-
lytes during sample preparation. However, there are
several drawbacks associated with the DHS method-
ology used in this investigation. In our method, ad-
dition of enzyme for hydrolysis increases the amount
of matrix in the sample. Because we did not separate
matrix from the analytes, unwanted matrix could
coelute with analytes of interest, causing ion
suppression. Matrix in the sample can also coat
stationary-phase particles in the analytical column,
leading to decreased interaction between the analyte
molecules and column particles. As the number of
injections on a column increases, more matrix is de-
posited, causing partial column blockage that results
in increased solvent back-pressure and decreased
column life. In our experience, columns last for
300–400 injections.
MATRIX EFFECT
Previous publications that used HRMS and libraries
with hundreds to thousands of compounds did not
perform matrix-effect studies (2, 5–7, 16 ) on each
analyte in the library. In our experience, having a
larger database with no matrix effects studies se-
verely limits the utility of these databases. We were
concerned about matrix effects using DHS and thus
selected samples from 13 different patients repre-
senting worst-case scenarios and 5 healthy volunteer
samples for spiking experiments. All 5 samples from
healthy volunteers were found to be negative for the
61 analytes. The 13 patient samples showed a total of
13 positive results for 10 different analytes. These 13
positives were excluded from the matrix effect study,
e.g., if a sample was positive for morphine, then after
spiking 61 analytes in that sample, the responses of
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Table 1. List of analytes studied and matrix effects in specimens obtained from healthy individuals (effect 1)
and patient’s specimens selected because of their abnormal color and turbidity (effect 2).a
Analyte
Matrix effect 1, % Matrix effect 2, %
Min Max Median Min Max Median
6-Acetylmorphine 27 64 53 45 88 75
7-Aminoclonazepam 8 52 44 36 85 66
Amitriptyline 11 14 5 18 51 40
Amphetamine 11 54 42 46 95 74
Atenolol 20 47 38 33 91 67
Benzoylegonine 14 53 46 33 81 67
Buprenorphine 33 12 12 3 44 29
Carisoprodol 4 26 15 24 59 46
Citalopram 22 39 34 41 73 57
Codeine 4 53 33 5 100 65
Cyclobenzaprine 17 21 10 17 63 39
Dextromethorphan 18 38 32 24 73 54
Diazepam 20 1 7 7 44 25
Diltiazem 9 14 2 12 51 36
Doxepine 8 27 18 21 65 46
EDDPb 15 16 7 21 51 41
Fentanyl 10 26 17 11 70 48
Flunitrazepam 12 32 29 28 95 57
Hydrocodone 33 80 69 68 94 84
Hydromorphone 32 59 57 38 85 75
Ketamine 34 66 48 32 79 71
Lorazepam 3 34 20 20 60 47
MDA 75 87 79 79 94 72
MDEA 10 39 35 24 81 57
MDMA 14 56 49 57 99 79
MDPV 10 22 17 21 78 49
Meperidine 6 30 23 31 76 55
Mephedrone 17 60 40 27 77 59
Meprobamate 8 31 27 37 80 55
Methadone 14 17 14 19 50 41
Methamphetamine 16 50 45 57 99 77
Methylone 3 41 31 32 80 61
Methylphenidate 4 28 23 37 79 50
Metoprolol 4 29 27 22 67 51
Morphine 16 61 50 36 97 76
Norbuprenorphine 16 53 49 26 77 67
Nordiazepam 12 29 25 19 53 42
Norfentanyl 43 69 55 27 84 70
Norhydrocodone 81 92 88 75 100 95
Normeperidine 11 28 23 30 76 57
Noroxycodone 49 72 66 54 93 83
Continued on page 1119
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all analytes, except morphine, were investigated for
matrix effect.
Spiking experiment. Typical urine drug concentrations
observed in intoxication cases in the emergency de-
partment are often in the microgram-per-milliliter or
higher range. Analytes can be detected with relative
ease, even in the presence of ion suppression, if present
at a sufficiently high concentration. However, matrix
effects canbe profoundwhen the analyte concentration is
relatively low; consequently, we decided to spikematrices
at 100 and 1000 ng/mL. Because 100 ng/mL was the
lowest concentration tested in human urine samples
that gave positive results meeting our acceptance crite-
ria, we consider this concentration to be our limit of
detection for most drugs, with the exception of a few
compounds where the limit of detection was between
100 and 1000 ng/mL.
DI water. To obtain signal intensity data without a
matrix, DI water was spiked with all 61 analytes at
100 and 1000 ng/mL and processed with the DHS
method. At 100 ng/mL, all analytes were identified
with their respective fragment ions except mor-
phine, norpropoxyphene, and tramadol. These 3
analytes did not show fragment ions in the absence
of sample matrix. For the spiking experiment of 61
analytes at 1000 ng/mL, all analytes were detected
with their respective fragment ions.
Healthy volunteer–spiked samples. All 5 samples were
spiked at 100-ng/mL concentration with the 61 ana-
lytes and processed with the DHS method. The re-
sponses of each analyte were compared with the re-
sponse from spiked DI water. Table 1 shows that there
was a wide range of matrix effects in samples from
healthy donors. We observed ion suppression that
ranged from zero to 100%. In addition, we observed
ion enhancement of up to 33%. Of the 61 analytes
spiked into these 5 samples, buprenorphine (twice),
norbuprenorphine (3 times), and norhydrocodone (4
times) failed to show a fragment ion, whereas mepro-
bamate and propoxyphene failed once each to show
Table 1. List of analytes studied and matrix effects in specimens obtained from healthy individuals (effect 1) and
patient’s specimens selected because of their abnormal color and turbidity (effect 2).a (Continued from page 1118)
Analyte
Matrix effect 1, % Matrix effect 2, %
Min Max Median Min Max Median
Norpropoxyphene 2 100 66 50 100 100
Nortriptyline 13 16 13 15 58 43
Oxazepam 3 34 29 25 67 53
Oxycodone 29 68 59 66 98 84
Oxymorphone 40 72 62 59 94 87
Phencyclidine 4 27 23 28 78 52
Promethazine 1 29 22 22 61 48
Propoxyphene 16 100 9 18 100 43
Propranolol 10 35 27 33 80 55
Quetiapine 2 36 8 3 52 28
Tapentadol 7 34 33 38 89 56
Temazepam 17 25 16 13 50 38
Tramadol 1 25 17 24 63 50
Trazadone 5 66 58 22 82 64
Venlafaxine 0 46 37 26 80 62
Verapamil 20 13 4 5 42 27
Zaleplon 4 42 35 28 78 65
Zolpidem 19 11 7 10 57 37
Zopiclone 5 56 42 25 86 70
-Hydroxyalprazolam 4 42 30 27 69 54
a Matrix effect formula: 100  [(response in specimen/response from spiked DI water)  100]. Negative matrix effect indicates an increase in the response.
b EDDP, 2-ethylidine-1,5dimethyl-3,3-diphenylpyrrolidine; MDEA, 3,4-methylenedioxy-N-ethylamphetamine; MDMA, 3,4-methylenedioxy-N-methylamphetamine;
MDPV, methylenedioxypyrovalerone.
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related protonated analyte. As seen with the spiked DI
water samples, tramadol and morphine failed to show
fragment ions in all 5 samples. For spiking at 1000 ng/
mL, all analytes (protonated analyte as well as at least 1
fragment) were detected in all 5 samples.
Spiked patient samples. Thirteen patient samples, se-
lected because they were abnormally colored or had
precipitates, were spiked at 100-ng/mL concentration
and processed with the DHS method. Similar to sam-
ples from healthy donors, ion suppression varied
widely in these samples. Thirty-seven of 61 analytes
consistently showed fragments ions in all samples.
Twenty-four of 61 analytes failed to show fragments in
1 or more samples. As in the DI water samples, mor-
phine, tramadol, and norpropoxyphene failed to show
fragments in all 13 samples. Fragmentation of trama-
dol led to only 1 fragment atm/z 58, which failed to be
detected on a consistent basis. Because of its smallm/z,
it was difficult to distinguish from the background
noise.
After spiking at 1000 ng/mL, all analytes showed
their protonated adduct as well as fragment ions,
except codeine (once), 3,4-methylenedioxyamp-
hetamine (MDA) (4 times), methylphenidate (once),
morphine (4 times), norhydrocodone (once), and trama-
dol (3 times) failed to show fragment ion.
ANALYTICAL SPECIFICITY
The 61 analytes were divided into 6 groups (5 10 and
1  11). Each group contained chromatographically
resolved analytes. Data from each group were screened
for 61 analytes. All spiked analytes showed positive re-
sults. We did not observe any (false) positives for ana-
lytes that were not spiked in respective groups.
PATIENT SAMPLE DATA ANALYSIS
ULPC-TOF (MSE) data were analyzed with UNIFI
software. The data were processed with a retention
time window of0.2 min and20 ppm window and
fragment ion with 5 ppm mass accuracy. To ensure
that matrix effects were not obscuring peaks, we veri-
fied that the protonatedmolecular ion of the 5 internal
standards, which spanned the retention time of inter-
est, were present at the expected retention time. The
processed data were then sorted with various filters.
We evaluated the following: (a) mass accuracy of20
ppm for protonated analyte combined with a retention
timematch of0.2 min; (b) mass accuracy of5 ppm
for protonated analyte combined with a retention time
match of 0.2 min; (c) mass accuracy of 5 ppm for
protonated analyte combined with a retention time
match of 0.2 min and 1 fragment ion (5 ppm);
and (d) isotope cluster intensity and ppmmatch. Typ-
ical processed MSE spectra are shown in Fig. 1.
Eleven samples (sample set 1) that were positive
for various opiates by LC-MS/MS were analyzed by
UPLC-TOF-MS DHS. The reference method identi-
fied 55 positives (Table 2). Table 2 also shows that, as
the requirements for identification becamemore strin-
gent, the number of false-positive UPLC-TOF-MS re-
sults decreased. For example, in the case of hydro-
codone, there were 3 false-positive UPLC-TOF-MS
Fig. 1. Sample data processed by UNIFI show mass spectra of positively identified analyte (temazepam).
Top spectrum, low-energy scan mass spectrum showing an identified protonated analyte (m/z 301.0747) for temazepam;
bottom spectrum, high-energy scan mass spectrum showing 3 identified fragment ions of temazepam at m/z 193.0892,
228.0576, and 255.0692.
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results when the only criteria used for identification
were a retention time0.2 min and20 ppm proton-
ated analyte match (5 matches vs 2 matches with the
reference method). With requirements of a retention
time0.2min and5 ppmprotonated analytematch,
there were only 2 false-positive results, and when a
fragment ion match (5 ppm) was included, there
were no false-positive results. This finding was consis-
tent with all of the sample sets, and because these crite-
ria provided the highest number of true positives with
zero false positives, they became the identification cri-
teria we used for the rest of the study. UPLC-TOF-MS
was able to identify 91% (50/55) of the true positives in
the opiate data set by use of the requirements of a 5
ppmprotonated analytematch, with a0.2min reten-
tion time and a5 ppm fragment ionmatch (Table 2).
By these criteria, a total of 5 false negatives were also
encountered. In 4 cases, false negatives were due to
absence of a fragment ion, whereas in 1 case, the
analyte ion failed to be detected. There were 45 ad-
ditional positives in these 11 samples (see online
Supplemental Table 1). We confirmed these posi-
tives by an MRM LC-MS/MS (UPLC-Xevo TQ-S)
assay developed specifically for this purpose.
Table 2. Comparison of number of positive results for opiate specimens (sample set 1) obtained




positives Comments20 ppm 5 ppm 5 ppm, fragment
6-Acetylmorphine 3 3 3 3
Codeine 4 4 4 4
EDDPb 4 4 4 4
Fentanyl 5 5 5 5
Hydrocodone 5 4 2 2
Hydromorphone 8 7 6 8 NF 106 ng/mL, NI 263 ng/mL
Methadone 4 4 4 4
Morphine 7 7 7 7
Norfentanyl 5 5 3 5 NF 79 and 95 ng/mL
Oxycodone 6 6 6 6
Oxymorphone 9 9 6 7 NF 234 ng/mL
Total 60 58 50 55
a Reference results obtained using MRM LC-MS/MS. Reference positives are based on the cutoff concentrations listed in online Supplemental Table 2.
b EEDP, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; NF, no fragment (for identified protonated analyte); NI, not identified (protonated analyte).
Table 3. Comparison of number of positive results for benzodiazepine specimens (sample set 2) obtained




positives Comments20 ppm 5 ppm 5 ppm, fragment
7-Aminoclonazepam 3 2 2 3 NI 5.02 ppm errorb
Lorazepam 3 3 3 3
Nordiazepam 9 9 8 9 NF 24 ng/mL
Oxazepam 10 10 10 10
Temazepam 9 9 9 9
-Hydroxyalprazolam 2 2 2 2
Total 36 35 34 36
a Reference results obtained using MRM LC-MS/MS. Reference positives are based on the cutoff concentration listed in online Supplemental Table 2.
b NI, not identified (protonated analyte); NF, no fragment (for identified protonated analyte).
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Ten patients’ samples (sample set 2) positive for
benzodiazepines by LC-MS/MS were analyzed by the
UPLC-TOF-MS method. Ninety-four percent (34/36)
of the true positives were confirmed by UPLC-
TOF-MS (Table 3). One of the false negatives was due
to mass error of 5.02 ppm, which was just above the set
criteria of5 ppm. The other false negative for nordi-
azepam was due to its low concentration (24 ng/mL).
Twenty-one additional drugs identified by UPLC-
TOF-MS were subsequently confirmed by the LC-
MS/MS method (see online Supplemental Table 1).
We also analyzed 15 postmortem urine samples
(sample set 3). Ninety-two percent (49/53) of the true-
positive results were confirmed by our analysis (Table
4). In4 incidences, theanalysis failed toproduce fragment
ion information.Those falsenegatives couldbedue to low
concentration of analytes, ion suppression, or both. We
could not confirm/hypothesize reasons for the lack of the
fragment ions because only qualitative results were avail-
able from the reference laboratory for this data set. The
UPLC-TOF-MS method identified 38 additional drugs
that were not identified by the referencemethod (see on-
line Supplemental Table 1). All of these additional posi-
tives were confirmed by LC-MS/MS.
Twenty-five pain management samples (sample
set 4) had a total of 131 true positives (Table 5) for 38
different analytes. The UPLC-TOF-MS analysis con-
firmed 92% (120/131) of the true positives reported.
There were 38 additional positives tentatively identi-
fied with the UPLC-TOF-MS method that were not
initially detected with the referencemethod (see online
Supplemental Table 1). These additional positives were
confirmed by a targeted LC-MS/MS.
As expected, the number of false positives de-
creased as we used more stringent identification crite-
ria. Use of a wider mass accuracy window (20 ppm)
Table 4. Comparison of number of positive results for postmortem specimens (sample set 3) obtained




positive Comments20 ppm 5 ppm 5 ppm, fragment
6-Acetylmorphine 11 9 6 8 2 NFb
Amphetamine 2 2 2 2
Atenolol 1 1 1 1
Benzoylecgonine 1 1 1 1
Citalopram 1 1 1 1
Codeine 9 8 8 8
EDDP 1 1 1 1
Fentanyl 2 2 1 1
Hydrocodone 3 3 0 1 NF
Ketamine 1 1 1 1
Meprobamate 1 1 1 1
Methadone 1 1 1 1
Methamphetamine 4 4 2 2
Morphine 11 11 11 12 NF
Norfentanyl 3 3 1 1
Norhydrocodone 1 1 1 1
Oxycodone 4 4 3 3
Oxymorphone 5 5 2 2
Promethazine 1 1 1 1
Propranolol 2 2 1 1
Quetiapine 1 1 1 1
Tramadol 4 4 2 2
Total 70 67 49 53
a Reference results obtained using GC/MS. Reference positives are based on the cutoff concentration listed in online Supplemental Table 2.
b NF, no fragment (for identified protonated analyte); EEDP, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine.
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Table 5. Comparison of number of positive results for pain management specimens (sample set 4) obtained




positives Comments20 ppm 5 ppm 5 ppm, fragment
6-Acetylmorphine 1 1 1 2 NI 30 ng/mLb
7-Aminoclonazepam 4 4 3 4 NF 234 ng/mL
Amitriptyline 2 2 2 2
Amphetamine 4 4 3 3
Benzoylegonine 9 7 3 3
Buprenorphine 4 4 3 3
Carisoprodol 5 4 2 2
Codeine 3 2 2 2
Cyclobenzaprine 3 3 3 3
EDDP 5 4 3 3
Fentanyl 3 3 2 3 NF 3 ng/mL
Hydrocodone 5 5 5 5
Hydromorphone 6 6 6 6
Ketamine 1 1 1 1
Lorazepam 2 2 2 2
Meperidine 2 2 1 1
Meprobamate 4 3 3 3
Methadone 4 4 4 4
Methamphetamine 2 1 1 1
Methylone 5 5 2 2
Methylphenidate 2 2 2 2
Morphine 7 5 5 6 NF 128 ng/mL
Norbuprenorphine 8 4 2 4 NF 56 ng/mL; NI 76 ng/mL
Nordiazepam 4 4 3 3
Norfentanyl 3 2 2 2
Norhydrocodone 5 5 3 4 1 NF 635 ng/mL
Noroxycodone 14 11 10 10
Nortriptyline 2 2 2 2
Oxazepam 4 4 4 4
Oxycodone 11 10 10 10
Oxymorphone 10 10 9 10 NF 349 ng/mL
Phencyclidine 1 1 1 1
Tapentadol 4 4 2 2
Temazepam 3 3 3 3
Tramadol 4 2 2 2
Venlafaxine 1 1 1 1
Zolpidem 2 2 2 2
-Hydroxyalprazolam 7 7 5 8 NF 34 and 39 ng/mL; NI 31 ng/mL
Total 166 146 120 131
a Reference results obtained using MRM LC-MS/MS. Reference positives are based on the cutoff concentration listed in online Supplemental Table 2.
b NI, not identified (protonated analyte); NF, no fragment (for identified protonated analyte); EEDP, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine.
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with retention time gave the most false positives (57),
whereas a 5 ppm with retention time match had 31
false positives, and the addition of a fragment ion (5
ppm) reduced the false positives to zero. By the most
stringent criteria for identification, in a total of 18 in-
cidences the UPLC-TOF-MS analysis failed to obtain
fragment ion information for 9 different analytes (6-
acetylmorphine, hydrocodone, hydromorphone, mor-
phine, norbuprenorphine, norfentanyl, norhydro-
codone, oxymorphone, tramadol) even at relatively
higher concentrations. We believe that matrix effect is
the likely reason that these true positives failed to show
fragment ions with our analysis. These analytes had
relatively high (60%) ion suppression in our matrix
effect studies, except tramadol. Tramadol shows only 1
fragment in general atm/z 58.0652 and is usually found
in the background noise owing to its smaller molecular
weight. It is likely that the accurate mass of this ion is
heavily influenced by the neighboring noise, knocking it
out of the mass accuracy window. Also, all analytes that
the UPLC-TOF-MS method had difficulty identifying,
except tramadol and norfentanyl, have a morphine-like
core structure and require high energy for fragmentation
that generally results in many fragments with low signal-
to-noise ratios. For most of these analytes, there are im-
munoassays readily available. In routine practice, most
urine samples are screened by immunoassay panels be-
fore MS analysis. Consistent with the Society of Forensic
Toxicologists guidelines for identification of drugs in bi-
ological samples, we consider a result reportable if we ob-
tain a positive finding on immunoassay followed by re-
tention time (0.2 min) and a precursor ion (5 ppm)
matchonUPLC-TOF-MSanalysis (17).Wedidnot iden-
tify any additional positives related to analytes that should
have been detected by the methods of the reference
laboratories.
Addition of the isotope pattern can be useful in
HRMS analyses (7 ). We also investigated the useful-
ness of isotope pattern (intensity and mass accuracy of
isotope cluster). For the method we developed, the re-
sults for isotope pattern did not add value, primarily
because of the low signal-to-noise ratio for isotope
clusters at lower limits of detection. For example,
UPLC-TOF-MS analysis would confirm the presence
of morphine by mass accuracy of5 ppm for proton-
ated analyte with a retention time match of 0.2 min
and 1 fragment ion (5 ppm) but would fail the
isotope cluster intensity and mass accuracy criteria.
Adding isotope cluster criteria did not improve the
analysis compared with the criteria that included a re-
tention time match (0.2 min) combined with a par-
ent ion (5 ppm match) and at least 1 fragment ion
(5 ppm match).
Conclusions
In our experiments, fragment ion informationwas crit-
ical for eliminating false-positive results. MSE incorpo-
rates fragment ion information in HRMS-based drug
screening with an untargeted approach. By use of a
collision energy ramp, MSE eliminates the need to op-
timize collision energies for individual analytes. The
combination of a low- and high-energy scan helps to
unambiguously identify analytes. A limitation of MSE
is that some analytes, such as morphine, do not yield
fragment ions of high abundance. DHS sample prepa-
ration worked well with our UPLC-TOF-MS method,
showing 92% confirmation of true positives, with the
ability to identify other drugs missed by the reference
methods. Themethodwe developed is fast, simple, and
cheap, but is subject to ion suppression, especially
when challengedwith abnormal urine samples. Prelim-
inary solid-phase extraction experiments demonstrated
reduced recovery of certain drugs, with minimal im-
provement inmatrix effects. Future studies should exam-
ine alternative sample preparation schemes to minimize
matrix effects while retaining the ability to detect a wide
variety of potential intoxicants.
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